Vertex Pharma (VRTX) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Vertex Pharma (VRTX) Tops Q2 EPS by 4c

Vertex Reports Second Quarter 2015 Financial Results

July 29, 2015 4:01 PM EDT

-Second quarter 2015 total revenues of $166 million, including net product revenues of approximately $155 million for KALYDECO® (ivacaftor) in cystic fibrosis-

-Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million-

-ORKAMBI (lumacaftor/ivacaftor) launch underway following FDA approval on July 2-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2015. Vertex also increased its financial guidance for total 2015 KALYDECO® (ivacaftor) revenues and reiterated its prior guidance for non-GAAP operating expenses. Key financial results include:

       ... More